ÀÇ·áÁø ã±â
¾Æ·¡ °Ë»öÀ» ÅëÇØ Á¤È®ÇÏ°í ºü¸£°Ô ÀÇ·áÁøÀ» °Ë»öÇÒ ¼ö ÀÖ½À´Ï´Ù.
Áø·á°ú ¾È³»
[¹®ÀÇÀüÈ] 1577-9966
Áø·á°ú¸¦ ¾È³»ÇØ µå¸³´Ï´Ù. Ŭ¸¯ ½Ã ÇØ´ç Áø·á°úÀÇ ÀÚ¼¼ÇÑ »çÇ×À» º¸½Ç ¼ö ÀÖ½À´Ï´Ù.
°£¼¾ÅÍ
-
[SCI]
Um SH BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A
Jung YK, Jung CH, Seo YS, Kim JH, Kim TH, Yoo YJ, Kang SH, Yim SY, Suh SJ, An H, Yim HJ, Yeon JE, Byun KS
/ Um SH BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A
/ 201509
-
[SCI]
Risk Factors for Developing Hyponatremia During Terlipressin Treatment: A Retrospective Analyses in Variceal Bleeding
Yim SY, Seo YS, Jung CH, Kim TH, Kim ES, Keum B, Kim JH, An H, Yim HJ, Yeon JE, Jeen YT, Lee HS, Chun HJ, Byun KS, Um SH, Kim CD, Ryu HS
/ Risk Factors for Developing Hyponatremia During Terlipressin Treatment: A Retrospective Analyses in Variceal Bleeding
/ 49(7):607-12
/ 201508
-
[SCI]
Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma
Ji J1, Eggert T, Budhu A, Forgues M, Takai A, Dang H, Ye Q, Lee JS, Kim JH, Greten TF, Wang XW
/ Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma
/ 62(2):481-95
/ 201508
-
[SCI]
Risk Factors for Developing Hyponatremia During Terlipressin Treatment: A Retrospective Analyses in Variceal Bleeding
Yim SY1, Seo YS, Jung CH, Kim TH, Kim ES, Keum B, Kim JH, An H, Yim HJ, Yeon JE, Jeen YT, Lee HS, Chun HJ, Byun KS, Um SH, Kim CD, Ryu HS
/ Risk Factors for Developing Hyponatremia During Terlipressin Treatment: A Retrospective Analyses in Variceal Bleeding
/ 49(7):607-12
/ 201508
-
[SCI]
Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma
/ Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma
/ 16(3):465-522
/ 201506